Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes.
Adalimumab
Guselkumab
Palmoplantar pustulosis
Pustulotic arthro-osteitis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
27 10 2022
27 10 2022
Historique:
received:
18
06
2022
accepted:
20
10
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
1
11
2022
Statut:
epublish
Résumé
We compared the treatment effectiveness between guselkumab and adalimumab in patients with pustulotic arthro-osteitis (PAO). In addition, we performed peripheral blood immunophenotyping to elucidate the immunological background and analyzed the impact of therapeutic drugs to verify the validity of immunological phenotypes as therapeutic targets. Patients were treated with guselkumab 100 mg (guselkumab group; n = 12) and adalimumab 40 mg (adalimumab group; n = 13). Arthritis disease activity, skin lesion activity, and patient-reported outcomes (PROs) were evaluated and compared between the two groups. The retention rate and adverse events were evaluated. Comprehensive phenotyping of peripheral immune cells was performed in both groups, and phenotypes were compared before and after treatment. At 6 months, both groups showed significant improvement in arthritis disease activity and PROs. In the guselkumab group, skin symptoms significantly improved. The 6-month continuation rates were 91.7% (11/12) and 69.2% (9/13) in the guselkumab and adalimumab groups, respectively. Adverse events occurred in 2/12 and 5/13 patients in the guselkumab (16.7%) and adalimumab (38.5%) groups, respectively. Peripheral blood immunophenotyping showed that the proportion of activated T helper (Th) 1 cells was significantly lower in patients with PAO than in healthy controls and that the proportion of activated Th17 cells was significantly higher in patients with PAO, which significantly decreased after treatment with guselkumab. Although guselkumab and adalimumab have comparable efficacy for PAO, their impact on immunophenotypes varies.
Identifiants
pubmed: 36303202
doi: 10.1186/s13075-022-02934-3
pii: 10.1186/s13075-022-02934-3
pmc: PMC9609190
doi:
Substances chimiques
Adalimumab
FYS6T7F842
guselkumab
089658A12D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
240Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
deWaal AC, van de Kerkhof PCM. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatolog Treat. 2011;22(2):102–5.
doi: 10.3109/09546631003636817
Langley RG, Krueger GG, et al. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl 2):il18–23.
Sonozaki H, Kawashima M, et al. Incidence of arthro-osteitis in patients with pustulosis palmaris et plantaris. Ann Rheum Dis. 1981;40:554–7.
doi: 10.1136/ard.40.6.554
pubmed: 6800310
pmcid: 1000828
Akiyama T, Seishima M, et al. The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol. 1995;22:930–4.
doi: 10.1111/j.1346-8138.1995.tb03948.x
pubmed: 8648000
Murakami M, Hagdorsen E, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845–7.
doi: 10.1111/j.1600-0625.2011.01325.x
pubmed: 21732985
Bissonnette R, Poulin Y, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25:1402–8.
doi: 10.1111/j.1468-3083.2011.03984.x
pubmed: 21349113
Bissonnette R, Poulin Y, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7(10):940–6.
pubmed: 19112757
Tadashi T, Satomi K, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153–61.
doi: 10.1001/jamadermatol.2019.1394
Tadashi T, Satomi K, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol. 2018;154(3):309–16.
doi: 10.1001/jamadermatol.2017.5937
Yamamoto T, Fukuda K, et al. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. J Eur Acad Dermatol Venereol. 2020;34:2318–9.
doi: 10.1111/jdv.16355
pubmed: 32173916
pmcid: 7586986
Ikumi N, Hideki F, Tadashi T. Guselkumab improves joint pain in patients with pustulotic arthro-osteitis: a retrospective pilot study. J Dermatol. 2021;48:199–202.
doi: 10.1111/1346-8138.15632
pubmed: 33051886
Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28(10):1298–305.
doi: 10.1111/jdv.12272
pubmed: 24112799
Krueger GG, Langley RG, Leonardi C, CNTO 1275 Psoriasis Study Group, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92.
doi: 10.1056/NEJMoa062382
pubmed: 17287478
Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12:191–200.
doi: 10.1038/nri3158
pubmed: 22343568
pmcid: 3409649
Collamer AN, Guerrero K, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.
doi: 10.1002/art.23835
pubmed: 18576309
Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis(DAPSA). A brief review. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S48–50.
pubmed: 26471734
Reich K, Armstrong AW, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.
doi: 10.1016/j.jaad.2016.11.042
pubmed: 28057361
Blauvelt A, Papp KA, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.
doi: 10.1016/j.jaad.2016.11.041
pubmed: 28057360
Sofen H, Smith S, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J. Allergy Clin Immunol. 2014;133(4):1032–40.
doi: 10.1016/j.jaci.2014.01.025
pubmed: 24679469
Miyagawa I, Nakayamada S, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology. 2019;58(2):336–44.
doi: 10.1093/rheumatology/key069
pubmed: 29618121
Miyagawa I, Nakayamada S, et al. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: one year follow-up outcomes. Front Med. 2022 Jul;27(9):934937.
doi: 10.3389/fmed.2022.934937